In a transformative healthcare intervention aimed at dismantling astronomical treatment expenses, the Central Government has moved decisively to rein in the runaway retail prices of vital anti-cancer formulations. The National Pharmaceutical Pricing Authority (NPPA), functioning under the Ministry of Chemicals and Fertilizers, has granted in-principle approval to cap trade margins at 30% of the Maximum Retail Price (MRP) across identified non-scheduled oncology drugs. This landmark measure brings critical financial respite to families grappling with catastrophic out-of-pocket medical bills in major cancer hubs nationwide—from Tata Memorial Hospital in Mumbai and AIIMS in New Delhi to regional oncology centers across Lucknow, Chennai, Kolkata, and Hyderabad. By curbing predatory pricing embedded within pharmaceutical distribution chains, the administration aims to ensure that life-extending therapies become universally accessible rather than a devastating financial burden.

Curbing Massive Markups Reaching up to 700 Percent

The urgent pricing intervention was triggered by alarming market distortion data uncovered during regulatory scrutiny. An extensive cost-structure audit conducted by drug pricing watchdogs revealed that several non-scheduled cancer medicines carried an average trade markup of nearly 170%, with specific critical formulations reaching astronomical markups as high as 700% between factory production gates and retail pharmacy counters. Because non-scheduled medicines previously operated outside strict statutory ceiling prices, intermediaries and private hospital supply chains were able to exploit wide pricing spreads for massive profit margins. Invoking extraordinary public interest powers under Paragraph 19 of the Drugs (Prices Control) Order (DPCO), 2013, the pricing regulator resolved that consumer welfare must take precedence over unchecked trade profiteering.

Expected 20% to 70% Drop in Medicine MRPs

The direct outcome of this 30% trade margin ceiling is an immediate, sharp contraction in retail pharmacy bills for patients. Official estimates project that Maximum Retail Prices across the identified drug formulations will plummet by 20% to 70%, depending on the existing commercial markup of each specific brand. The sweeping price correction is estimated to unlock cumulative annual savings of approximately ₹2,500 crore directly into the hands of citizens undergoing chemotherapy, targeted therapies, and immunotherapy cycles. This reform expands significantly upon the pilot Trade Margin Rationalisation (TMR) exercise initiated in 2019, which regulated 42 non-scheduled cancer medicines, shaved prices by an average of 50% across more than 500 drug brands, and saved patients nearly ₹984 crore each year.

Streamlining Procurement Across Hospitals and Pharmacies

To enforce strict compliance on the ground, state drug controllers, district civil surgeons, and municipal health monitors across all states and union territories will oversee the rollout as the finalized list of covered therapeutic molecules is notified. Manufacturers and pharmaceutical distributors will be legally mandated to revise price tags downward and circulate updated price lists to retail chemists, private tertiary hospital chains, and cancer care clinics. The move complements existing affordability pillars, including the expanding Pradhan Mantri Bhartiya Janaushadhi Pariyojana network, recent customs duty exemptions on specialized oncology imports, and statutory ceiling limits already active on over 130 scheduled cancer medicines. By shutting down exploitative trade margins across the medical supply line, the policy establishes lasting transparency, ensuring that dignity, hope, and affordable healing remain within reach of every cancer warrior in the country.